Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High Concordance Between Two Companion Diagnostics Tests

17 Jun 2011

Abstract excerpt

The present study was done to investigate the concordance between the HER2 status measured by immunohistochemical analysis (HercepTest, DAKO, Carpinteria, CA) and fluorescence in situ hybridization (FISH; HER2 FISH pharmDx, DAKO) in a large study cohort (n = 681) of patients with high-risk breast cancer. A high agreement between immunohistochemical and FISH results was demonstrated. For the whole study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Biosensing Techniques and Applications
Share to HER2/EGFR in Cancer Research
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21685042
DOI: 10.1309/ajcpjpj8zwgdttwc

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High Concordance Between Two Companion Diagnostics TestsPMID 21685042Read ↗

HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Concordance analysis between HER2 immunohistochemistry and in situ hybridization in non-small cell lung cancer.Semantic proximity Read ↗

Unveiling the mysteries of HER2-low expression in breast cancer: pathological response, prognosis, and expression level alterationsSemantic proximity Read ↗

Single HER2-Positive Tumor Cells are Detected in Initially HER2-Negative Breast Carcinomas using the DEPArray™–HER2-FISH WorkflowSemantic proximity Read ↗

Exploring the Heterogeneity of HER2 gene status and Expression in Non-Positive Breast Cancer Patients: Insights from Immunohistochemistry and Fluorescence In Situ HybridizationSemantic proximity Read ↗

Validation of Dual-Color Dual In Situ Hybridization for HER2/neu Gene in Breast CancerSemantic proximity Read ↗

Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinomaSemantic proximity Read ↗

Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer SpecimensSemantic proximity Read ↗

Molecular Biological Determination of HER2 Status Using Both DNA and RNA Approaches. A Concordance Study with IHC AssessmentSemantic proximity Read ↗

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplificationSemantic proximity Read ↗

Determination of Hormone Receptors, Human Epidermal Growth Factor Receptor 2 and Ki67 Status in Invasive Breast Carcinoma: A Concordance Study between Immunohistochemistry, Fluorescence in Situ Hybridization, and GeneXpert® Breast Cancer STRAT4 AssaySemantic proximity Read ↗

Multi-institutional Assessment of Pathologist scoring HER2 ImmunohistochemistrySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.